• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Natera Inc.

    6/16/25 12:59:57 PM ET
    $NTRA
    Medical Specialities
    Health Care
    Get the next $NTRA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001646649
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Natera, Inc.
    SEC File Number
    001-37478
    Address of Issuer
    13011 MCCALLEN PASS
    BUILDING A SUITE 100
    AUSTIN
    TEXAS
    78753
    Phone
    650-249-9090
    Name of Person for Whose Account the Securities are To Be Sold
    Sheena Jonathan
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Charles Schwab & Co., Inc.
    3000 Schwab Way
    Westlake � TX � 76262
    90001481005.0013654658006/16/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    COMMON04/30/2012FOUNDERS SHARESISSUERCheckbox not checked900004/30/2012NA

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Jonathan Sheena
    C/O 13011 McCallen Pass,
    Building A Suit 100
    Austin � TX � 78753
    COMMON04/04/20253070408741.00
    JONATHAN SHEENA
    C/O 13011 McCallen Pass
    Building A Suite 100
    Austin � TX � 78753
    COMMON05/09/20253070491866.00
    JONATHAN SHEENA
    C/O 13011 McCallen Pass
    Building A Suite 100
    Austin � TX � 78753
    COMMON04/03/20253000417574.00
    JONATHAN SHEENA
    C/O 13011 McCallen Pass
    Building A Suite 100
    Austin � TX � 78753
    COMMON05/12/20253000474765.00

    144: Remarks and Signature

    Remarks
    This E-filing covers following 2 accounts: 4.5K SHARES -SOUTHDAKOTA TRUST COMPANY LLC CARALUNA 1 TRUST ACCT & 4.5K SHARES - SOUTH DAKOTA TRUST COMPANY LLC CARALUNA 2 TRUST ACCT
    Date of Notice
    06/16/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    06/07/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Jonathan Sheena

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $NTRA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTRA

    DatePrice TargetRatingAnalyst
    3/13/2025$251.00Outperform
    RBC Capital Mkts
    1/23/2025$200.00Overweight
    Barclays
    6/3/2024$142.00Buy
    Jefferies
    4/8/2024$117.00Buy
    Craig Hallum
    2/20/2024$68.00 → $85.00Strong Buy → Outperform
    Raymond James
    12/29/2023$75.00 → $85.00Buy
    BTIG Research
    12/14/2023$70.00Buy
    Guggenheim
    12/13/2023$70.00Outperform
    Wolfe Research
    More analyst ratings

    $NTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit

    Topline results from the trial show that Signatera-positive patients treated with atezolizumab (Tecentriq®) had statistically significant and clinically meaningful improvements in disease-free survival and overall survival IMvigor011 is the first prospective phase III study in muscle-invasive bladder cancer to read out that uses a personalized, ctDNA MRD*-guided approach Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced positive topline results from the randomized, phase III IMvigor011 clinical trial in muscle-invasive bladder cancer (MIBC). The trial is sponsored by Genentech, a member of the Roche Group. IMvigor011 utilizes the Sign

    8/18/25 6:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Reports Second Quarter 2025 Financial Results

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the second quarter ended June 30, 2025. Recent Financial Highlights Generated total revenues of $546.6 million in the second quarter of 2025, compared to $413.4 million in the second quarter of 2024, an increase of 32.2%. Product revenues grew 32.3% over the same period. Generated a gross margin of 63.4% in the second quarter of 2025, compared to a gross margin of 58.8% in the second quarter of 2024. Processed approximately 853,100 tests in the second quarter of 2025, compared to approximately 760,300 tests in the second quarter of 2024, an increase of 12.

    8/7/25 4:05:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

    Launch supported by strong assay performance in first milestone readout of the landmark EXPAND clinical trial Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test (NIPT) for inherited conditions. When a pregnant patient is identified as a carrier of a recessive single-gene condition, medical guidelines recommend partner testing in order to determine the risk for the baby to be affected by the condition1; however, in some cases the biological father is unavailable for testing. The Fetal Focus test was designed to address this unmet need. Now if a pregnant patient tests p

    8/7/25 7:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Natera with a new price target

    RBC Capital Mkts initiated coverage of Natera with a rating of Outperform and set a new price target of $251.00

    3/13/25 8:17:14 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Barclays initiated coverage on Natera with a new price target

    Barclays initiated coverage of Natera with a rating of Overweight and set a new price target of $200.00

    1/23/25 7:51:22 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Jefferies resumed coverage on Natera with a new price target

    Jefferies resumed coverage of Natera with a rating of Buy and set a new price target of $142.00

    6/3/24 8:16:05 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon was granted 1,675 shares and sold $136,027 worth of shares (875 units at $155.46), increasing direct ownership by 0.65% to 123,859 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    8/15/25 9:35:06 PM ET
    $NTRA
    Medical Specialities
    Health Care

    PRESIDENT, CHIEF BUS. OFFICER Fesko John sold $105,401 worth of shares (678 units at $155.46) and was granted 1,675 shares, increasing direct ownership by 0.66% to 152,747 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    8/15/25 9:35:05 PM ET
    $NTRA
    Medical Specialities
    Health Care

    CO-FOUNDER Sheena Jonathan sold $958,059 worth of shares (6,070 units at $157.84), decreasing direct ownership by 1% to 242,252 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    8/12/25 9:05:06 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.

    SCHEDULE 13G/A - Natera, Inc. (0001604821) (Subject)

    8/14/25 1:07:20 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Natera Inc.

    10-Q - Natera, Inc. (0001604821) (Filer)

    8/7/25 8:24:04 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Natera, Inc. (0001604821) (Filer)

    8/7/25 4:12:10 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Leadership Updates

    Live Leadership Updates

    View All

    Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer

    Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee

    6/5/23 11:06:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors

    Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations

    2/23/23 8:05:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology

    AUSTIN, Texas, May 24, 2022  /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera™ and incorporate it into standard medical practice across tumor types. "I am very pleased to welcome Dr. Liu to Natera," said Solomon Moshkevich, general manager of oncology at Natera. "As a highly reg

    5/24/22 8:03:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Financials

    Live finance-specific insights

    View All

    Natera Reports Second Quarter 2025 Financial Results

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the second quarter ended June 30, 2025. Recent Financial Highlights Generated total revenues of $546.6 million in the second quarter of 2025, compared to $413.4 million in the second quarter of 2024, an increase of 32.2%. Product revenues grew 32.3% over the same period. Generated a gross margin of 63.4% in the second quarter of 2025, compared to a gross margin of 58.8% in the second quarter of 2024. Processed approximately 853,100 tests in the second quarter of 2025, compared to approximately 760,300 tests in the second quarter of 2024, an increase of 12.

    8/7/25 4:05:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera to Report Its Second Quarter Results on August 7, 2025

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30, 2025, after the market closes on August 7, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information   Event:   Natera's Second Quarter 2025 Financial Results Date:   August 7, 2025 Time:   1:30 p.m. PT (4:30 p.m. ET) Live Dial-In:   1-888-770-7321 (Domestic) 1-929-201-7107 (International) Conference ID:   7684785 Webcast:  

    7/31/25 7:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Reports First Quarter 2025 Financial Results

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. Product revenues grew 37.1% over the same period. Generated a gross margin of 63.1% in the first quarter of 2025, compared to a gross margin of 56.7% in the first quarter of 2024. Processed approximately 855,100 tests in the first quarter of 2025, compared to approximately 735,800 tests in the first quarter of 2024, an increase of

    5/8/25 4:05:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Natera Inc.

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    11/14/24 4:02:50 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    6/7/24 12:07:25 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    2/14/24 4:06:56 PM ET
    $NTRA
    Medical Specialities
    Health Care